Philippe Mertz
Overview
Explore the profile of Philippe Mertz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
202
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mertz P, Boursier G, Hentgen V, Georgin-Lavialle S
J Allergy Clin Immunol Pract
. 2024 Dec;
13(3):522-532.
PMID: 39725312
Autoinflammatory diseases (AIDs) are characterized by dysregulation of innate immunity, leading to systemic inflammation. Familial Mediterranean fever (FMF) is the most common AID, associated with variants in exon 10 of...
2.
Elhani I, Calas L, Bejar F, Pieroni L, Kone-Paut I, Rossi-Semerano L, et al.
J Allergy Clin Immunol Pract
. 2024 Dec;
13(3):695-697.e1.
PMID: 39667435
No abstract available.
3.
Mertz P, Hentgen V, Boursier G, Elhani I, Calas L, Delon J, et al.
Rev Med Interne
. 2024 Aug;
46(3):155-163.
PMID: 39155178
Autoinflammatory diseases (AIDs) are conditions characterized by dysfunction of innate immunity, causing systemic inflammation and various clinical symptoms. The field of AIDs has expanded due to improved comprehension of pathophysiological...
4.
Mertz P, Hentgen V, Georgin-Lavialle S
Rheumatology (Oxford)
. 2024 Jul;
64(1):12-21.
PMID: 38950176
Introduction: Familial Mediterranean Fever (FMF) is the most common monogenic autoinflammatory disease characterized by recurrent fever and serosal inflammation. Although colchicine is the primary treatment, around 10% of FMF patients...
5.
Mertz P, Costedoat-Chalumeau N, Ferrada M, Moulis G, Mekinian A, Grayson P, et al.
Nat Rev Rheumatol
. 2024 May;
20(6):347-360.
PMID: 38698240
Relapsing polychondritis is a rare inflammatory disease characterized by recurrent inflammation of cartilaginous structures, mainly of the ears, nose and respiratory tract, with a broad spectrum of accompanying systemic features....
6.
Sztejkowski C, Sibilia J, Danion F, Mertz P, Elodie F, Kassegne L, et al.
Rheumatology (Oxford)
. 2023 Dec;
63(6):e185-e187.
PMID: 38070160
No abstract available.
7.
Kawka L, Sarmiento-Monroy J, Mertz P, Pijnenburg L, Rinagel M, Ugarte-Gil M, et al.
RMD Open
. 2023 Dec;
9(4).
PMID: 38056917
Background: Fatigue is reported as the most prevalent symptom by patients with systemic lupus erythematosus (SLE). Fatigue management is complex due to its multifactorial nature. The aim of the study...
8.
Jannot X, Gerber V, Hallynck X, Willaume T, Mertz P
Rheumatology (Oxford)
. 2023 Nov;
63(4):e126-e128.
PMID: 37966922
No abstract available.
9.
Mathian A, Felten R, Alarcon-Riquelme M, Psarras A, Mertz P, Chasset F, et al.
Joint Bone Spine
. 2023 Aug;
91(2):105627.
PMID: 37640261
The improved understanding of the molecular basis of innate immunity have led to the identification of type I interferons (IFNs), particularly IFN-α, as central mediators in the pathogenesis of several...
10.
Askanase A, Khalili L, Tang W, Mertz P, Scherlinger M, Sebbag E, et al.
Best Pract Res Clin Rheumatol
. 2023 Aug;
37(4):101865.
PMID: 37633826
Following better understanding of molecular pathways involved in the pathogenesis of Systemic lupus erythematosus (SLE), pharmaceutical companies have been investigating new targeted drugs for SLE. The purpose of this scoping...